GC Cell

GC Cell Receivables

The Accounts Receivable of GC Cell (144510.KQ) as of Nov 4, 2026 is 19.50 B KRW. In the previous year, Accounts Receivable was 32.67 B KRW — a change of -40.33% (lower).

Receivables

19.50 BKRW

YoY

-40.33%

Last updated:

Accounts Receivable of GC Cell is 2024 19.50 B KRW. Accounts Receivable of GC Cell was 2023 32.67 B KRW. It decreases by -40.33% lower compared to the previous year.

The GC Cell Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2017
5.24 B KRW
Jan 1, 2018
5.92 B KRW
Jan 1, 2019
7.00 B KRW
Jan 1, 2020
12.28 B KRW
Jan 1, 2021
61.64 B KRW
Jan 1, 2022
32.13 B KRW
Jan 1, 2023
32.67 B KRW
Jan 1, 2024
19.50 B KRW
The GC Cell Receivables history
YEARReceivablesYoY
19.50 BKRW-40.33%
32.67 BKRW+1.68%
32.13 BKRW-47.87%
61.64 BKRW+401.87%
12.28 BKRW+75.47%
7.00 BKRW+18.34%
5.92 BKRW+12.84%
5.24 BKRW+12.47%
4.66 BKRW+38.93%
3.36 BKRW+22.71%
2.73 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GC Cell Stock analysis

What does GC Cell do? GC Cell Corp generates revenue through four business segments. The Specimen Testing Service segment offers sample testing, clinical trial support, and veterinary testing services to clients in healthcare and research sectors. The Cell Therapy segment provides cell culture solutions and technology transfer services to biotechnology firms. The Cord Blood Storage segment delivers cord blood storage services primarily to expectant parents and medical institutions. The Other Business segment handles bio-logistics services and related operations for healthcare providers. The company's revenue streams are derived from direct contracts with healthcare organizations, biotech companies, and individual clients seeking specialized testing and storage solutions. Clients include hospitals, research institutions, and private individuals requiring cord blood preservation. The firm's business model focuses on providing specialized services within the life sciences sector without relying on external partnerships or third-party platforms. GC Cell Corp's product offerings are tailored to specific industry needs, with each segment targeting distinct client groups. The Specimen Testing Service segment serves clients needing laboratory analysis, while the Cell Therapy segment supports biotech innovation through technology transfer. The Cord Blood Storage segment caters to consumer demand for personal health preservation, and the Other Business segment facilitates logistics for medical supply chains. GC Cell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GC Cell stock

Accounts Receivable of GC Cell is 19.50 B KRW in 2024.

Accounts Receivable of GC Cell changed from 32.67 B KRW to 19.50 B KRW, representing a -40.33% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable GC Cell since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's GC Cell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — GC Cell

All Key Metrics — GC Cell